Get the Stockscreener App
13.88
2.16%
0.235
Mediwound Ltd stock is traded at $13.88, with a volume of 25,192.
It is up +2.16% in the last 24 hours and up +7.27% over the past month.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
See More
Previous Close:
$13.65
Open:
$13.77
24h Volume:
25,192
Relative Volume:
0.29
Market Cap:
$179.58M
Revenue:
$14.48M
Net Income/Loss:
$-26.11M
P/E Ratio:
-6.1463
EPS:
-2.2591
Net Cash Flow:
$-23.86M
1W Performance:
+4.46%
1M Performance:
+7.27%
6M Performance:
-16.04%
1Y Performance:
-22.61%
1-Day Range:
$13.50
$13.97
1-Week Range:
$13.00
$13.99
52-Week Range:
$12.52
$20.03
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDWD
Mediwound Ltd
|
13.91 | 176.23M | 14.48M | -26.11M | -23.86M | -2.2591 |
VRTX
Vertex Pharmaceuticals Inc
|
522.17 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
792.92 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
187.98 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
957.00 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
195.15 | 40.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-02-25 | Initiated | Alliance Global Partners | Buy |
| Feb-28-25 | Initiated | Craig Hallum | Buy |
| Jul-16-24 | Reiterated | Maxim Group | Buy |
| Dec-22-22 | Initiated | Maxim Group | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Sep-23-20 | Initiated | BTIG Research | Buy |
| Nov-28-16 | Initiated | Aegis Capital | Buy |
| Aug-17-16 | Initiated | Wells Fargo | Outperform |
| Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
Mediwound Ltd Stock (MDWD) Latest News
TD Cowen reiterates MediWound stock rating ahead of trial data By Investing.com - Investing.com Canada
MediWound Ltd. (MDWD) Stock Price, News, Quote & History - Yahoo! Finance Canada
MediWound Ltd. Receives Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid - marketscreener.com
MDWD Looks 11.4% Overvalued on GF Value™ - GuruFocus
Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) - TipRanks
Understanding the Setup: (MDWD) and Scalable Risk - news.stocktradersdaily.com
MediWound receives $3.3M from DoD for NexoBrid development By Investing.com - Investing.com Nigeria
MediWound Awarded Additional $3.3 Million from U.S. - GlobeNewswire
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification - Yahoo Finance
(MDWD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Director of MediWound (NASDAQ: MDWD) trades shares via spouse - Stock Titan
An FDA-approved burn treatment company’s CEO will join a New York fireside chat. - Stock Titan
Precision Trading with Mediwound Ltd. (MDWD) Risk Zones - Stock Traders Daily
Hungarian fund owns double-digit MediWound (MDWD) stake - Stock Titan
MediWound (NASDAQ: MDWD) seller Hess plans $50K, 3,958-share sale - Stock Titan
New Research Estimates a $4 Billion Market by 2028, and MediWound Thinks It May Have a Solution (Nasdaq - Benzinga
MediWound (MDWD) Q2 2026 Earnings Call Transcript - AOL.ca
MediWound (MDWD) Q2 2026 Results: The Available Earnings Metric Delivers a Beat in the Current Update; Closing Reaction: The Stock Records a 1.87% Increase in the Current UpdateRevenue Per Share - vinanet.vn
MediWound (MDWD) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Share-Price Check: Shares Move 1.87% Up on the DayNegative Surprise Momentum - dars.gov.et
What is HC Wainwright's Forecast for MediWound Q3 Earnings? - MarketBeat
Weekly Recap: Reaffirmed 2026 guidance and EscharEx Phase III enrollment - TradingView
MDWD Looks 30.8% Overvalued on GF Value™ - GuruFocus
Mediwound Ltd (MDWD) Stock News Today - TradingKey
MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - Moomoo
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30 - Moomoo
MediWound (MDWD) Stock Faces Cash Burn As Revenue Slips - simplywall.st
Wall Street Zen Downgrades MediWound (NASDAQ:MDWD) to Strong Sell - MarketBeat
MediWound Q2 2026 Earnings Call: Complete Transcript - Sahm
A Quick Look at Today's Ratings for MediWound(MDWD.US), With a Forecast Between $22 to $36 - Moomoo
MDWD Maintains by Oppenheimer -- Price Target Lowered to $30.00 - GuruFocus
T. Rowe Price Associates (MDWD) discloses 5.0% ownership in Mediwound common stock - Stock Titan
MediWound Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $36 - Moomoo
MediWound (MDWD) Earnings Call zu Q2 2026: VALU auf Kurs, Prognose bekräftigt - TradingKey
Key facts: MediWound Ltd. (MDWD) Q2 $3.09M rev; EscharEx $4B target - TradingView
Oppenheimer Adjusts Price Target on MediWound to $30 From $32, Keeps Outperform Rating - Yahoo Finance
Q2 2026 Mediwound Ltd Earnings Call Transcript - GuruFocus
Mediwound earnings missed by $0.03, revenue topped estimates - Investing.com Canada
MediWound (NASDAQ:MDWD) Issues Earnings Results - MarketBeat
MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record - GuruFocus
MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ... - ca.finance.yahoo.com
A. G. P. Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $22 - Moomoo
MediWound Q2 2026 Earnings Call Transcript - MarketBeat
MediWound Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: MediWound tops Q2 2026 revenue forecast as shares rise - Investing.com
Mediwound Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Mediwound Ltd. Reaffirms Revenue Guidance for the Full-Year 2026 - marketscreener.com
MediWound Q2 sales beat estimates; EPS miss widens as R&D rises - scanx.trade
MediWound Ltd. (MDWD) Q2 FY2026 earnings call transcript - Yahoo Finance
Mediwound Ltd Stock (MDWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):